Hong Kong develops ‘world’s first’ nasal spray for rapid stroke aid

Key Concepts

• Nano-Micron Technology: A specialized drug delivery system that aggregates nanoparticles into micron-sized particles to optimize transport from the nose to the brain.
• Neuroprotective Therapy: A treatment approach aimed at preserving neuronal integrity and preventing cell death during an ischemic event.
• Pre-hospital Emergency Treatment: Medical intervention administered at the scene of an emergency (e.g., by caregivers or ambulance staff) before reaching a hospital.
• Ischemic Stroke: A condition caused by a blockage in an artery supplying blood to the brain.
• Hemorrhagic Stroke: A condition caused by bleeding in the brain.
• GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards.

---

1. Overview of the Innovation

Researchers at the University of Hong Kong, led by Professor Aviva Chow, have developed a novel nasal spray designed to provide immediate, pre-hospital treatment for stroke patients. The spray utilizes "nano-micron" technology to deliver neurotherapeutic medicine directly to the brain, aiming to reduce brain damage by over 80% and significantly improve survival rates.

2. Mechanism of Action

• Drug Composition: The spray contains neuroprotective drugs with anti-inflammatory, antioxidant, and anti-apoptotic (preventing programmed cell death) properties.
• Delivery System: While standard nanoparticles are often too small for efficient nose-to-brain delivery, the team developed "nano-micron" technology. By engineering these particles into a micron size, the drug is effectively transported to the ischemic brain, where it protects neurons from dying during the stroke.
• Ease of Use: The device is portable and designed for one-push administration, allowing caregivers or ambulance personnel to treat the patient immediately upon the onset of symptoms.

3. Comparison with Current Standards

• Current Limitations: Existing treatments for ischemic stroke—intravenous TPA (tissue plasminogen activator) to dissolve blood clots or surgical intervention to remove clots—can only be performed within a hospital setting.
• The "Game Changer": The nasal spray acts as an adjunct therapy rather than a replacement for current treatments. Its primary value lies in its ability to provide neuroprotection during the critical "golden hour" before the patient reaches the hospital, thereby preserving brain tissue that would otherwise be lost.

4. Clinical Significance and Scope

• Target Population: In Hong Kong, there are approximately 25,000 stroke cases annually, a figure rising due to an aging population. In mainland China, stroke is the leading cause of death and disability.
• Versatility: Because the drug is neuroprotective rather than clot-dissolving, it has the potential to be used for both ischemic and hemorrhagic stroke patients, pending further research and data collection.

5. Development Roadmap and Future Goals

• Current Status: The team has completed the majority of preclinical studies, including formulation design, optimization, cellular studies, and animal trials.
• Next Milestones:
  • GMP Manufacturing: The team is currently seeking an industrial partner to facilitate Good Manufacturing Practice (GMP) production to ensure quality compliance.
  • Clinical Trials: Human clinical trials are projected to begin around 2025.
• Long-term Vision: Following clinical approval, the goal is to deploy the spray in emergency departments and ambulances, eventually expanding to nursing homes and, ultimately, making it available at the community level (e.g., pharmacies) for individuals to keep on standby.

6. Synthesis

The development of this nasal spray represents a paradigm shift in stroke management by moving the window of intervention from the hospital to the point of injury. By focusing on neuroprotection through advanced particle engineering, the researchers aim to mitigate the long-term disability associated with strokes. The transition from successful animal models to human clinical trials in 2025 will be the critical next step in validating this technology for widespread emergency use.